NCT04387084: Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Skin
Additional Notes: 
Exclusions: Patients with known brain metastases; Patients who have had more than 2 lines of prior systemic therapy (not including neoadjuvant or adjuvant therapy); Patients with prior treatment with any agent that blocks the PD-1 or PD-L1 pathway

Comments are closed.

Up ↑